DiscGenics Company Update

April 30, 2018

Dear Friends of DiscGenics, 

We officially commenced clinical evaluation of IDCT for degenerative disc disease last month, and just yesterday, announced the first patient has been treated in our U.S. Phase I/II trial. This is a critical milestone, as the study will not only help advise us on the safety and tolerability of IDCT at varying dosage levels, but will begin to give us some insight into the potential effect of IDCT on lower back pain and disability. 

In addition, we presented data from two animal studies at the Orthopedic Research Society (ORS) Annual Meeting held last month in New Orleans. The studies highlighted the safety and regenerative capacity of Discogenic Cells, which are the active ingredient in IDCT. 

I invite you to review these and the additional items below and contact us if you have any questions.

As always, I would like to thank you on behalf of the entire DiscGenics team for your interest and support, and look forward to updating you on our continued efforts to transform the way millions of patients suffering from the debilitating effects of chronic back pain are treated.

Sincerely,

Flagg Flanagan

Chief Executive Officer and Chairman of the Board 

LEARN MORE